Aptose Biosciences Inc. (TSX:APS)

Market Cap	5.67M
Revenue (ttm)	n/a
Net Income (ttm)	-26.87M
Shares Out	2.55M
EPS (ttm)	-12.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	384
Average Volume	6,117
Open	2.260
Previous Close	2.220
Day's Range	2.100 - 2.260
52-Week Range	1.020 - 12.600
Beta	0.60
RSI	55.37
Earnings Date	Mar 27, 2026

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, wh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 13
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: APS

Financial Performance

Financial numbers in USD